Anlotinib combined with penpulimab in the treatment of advanced adult thoracic spinal osteosarcoma: a case report
This case demonstrates that sequential molecular targeted therapy and immunotherapy following chemoradiation can yield remarkable clinical outcomes, offering a novel therapeutic option for advanced spinal osteosarcoma. However, interindividual variations in treatment response underscore the need for future research to identify predictive biomarkers for patient stratification.
Authors
- Jia Qu (ORCID: https://orcid.org/0000-0002-3472-0044)
- X Li
- Xiaojuan Li (ORCID: https://orcid.org/0000-0002-2668-3044)
- Xiaochun Chen (ORCID: https://orcid.org/0000-0001-5146-9288)
- Haiying Zhao (ORCID: https://orcid.org/0009-0007-4317-0033)
- Zhiping Yuan
- Chuan Lin (ORCID: https://orcid.org/0009-0005-4204-5375)
Institutions
- Second People’s Hospital of Yibin (CN)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2025-07-30
- DOI
- https://doi.org/10.3389/fphar.2025.1599496
- Citations
- 2
- Primary Topic
- Sarcoma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 3.04
Funders
- Wu Jieping Medical Foundation